Telemedicine COVID-19
Telemedicine for Cancer Patients
To help keep our patients, staff and community healthy during the COVID-19 pandemic, Rutgers Cancer Institute is utilizing telemedicine to continue to care for our patients. Read more
All Rutgers Cancer Institute appointments will take place at the Jack & Sheryl Morris Cancer Center. Please proceed to 15 Division Street New Brunswick, NJ to valet park or 18 Hardenberg Street, New Brunswick, NJ for self-parking in the garage.
Refer to your MyChart portal for appointment details or call 732-235-2465 for assistance.
Please read our guidelines before visiting Rutgers Cancer Institute.
To help keep our patients, staff and community healthy during the COVID-19 pandemic, Rutgers Cancer Institute is utilizing telemedicine to continue to care for our patients. Read more
In order to help keep our patients, staff and community healthy during the COVID-19 pandemic, Rutgers Cancer Institute of New Jersey, in partnership with RWJBarnabas Health, is utilizing telemedicine for surveillance and follow-up appointments for existing cancer patients. When appropriate, telemedicine appointments for initial consults for patients with a new cancer diagnosis are also offered.
Andrew M. Evens, DO, MSc, FACP, Associate Director for Clinical Services and Director, Lymphoma Program, Rutgers Cancer Institute of New Jersey; Medical Director, Oncology Service Line, RWJBarnabas Health; and Professor of Medicine, Rutgers Robert Wood Johnson Medical School.
Below are some Nursing Education Resources, highlighting online programs.
As New Jersey’s only National Cancer Institute-designated Comprehensive Cancer Center, Rutgers Cancer Institute of New Jersey together with RWJBarnabas Health is the state’s leading authority on cancer. As such, we want to help our patients navigate and better understand how the coronavirus may impact them.
Dr. Gulhati received a Bachelor of Science in Physiology (Honors) from The University of British Columbia. As an undergraduate, he performed research in the laboratory of Dr. Poul Sorensen to identify novel interaction partners of the chimeric oncoprotein, ETV6-NTRK3, which is implicated in cancers of varying lineages. He subsequently completed Physician-Scientist training in the combined MD/PhD program at The University of Texas.
Jackie Harris
Research Administrative Assistant
harrisja@cinj.rutgers.edu
The Gulhati lab is focused on basic and translational research in gastrointestinal cancers. Ongoing projects in the lab are focused on:
Pancreatic Cancer
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive and lethal malignancy that will soon be the second leading cause of cancer death and remains remarkably resistant to all forms of therapy. There is a pressing need to gain a deeper understanding of the fundamental biology underlying this recalcitrant disease and uncover novel treatment strategies with sustained therapeutic efficacy.
Visit the Tobacco Dependence Program page to learn how to quit smoking today. Read more